We are pleased to invite you to read the 2021–2022 selected papers in Cancers (ISSN: 2072-6694) in the Section “Cancer Immunology and Immunotherapy”. The paper list is as follows:

1. “Recombinant Attenuated Salmonella enterica as a Delivery System of Heterologous Molecules in Cancer Therapy”
by Elayne Irene, Becerra-Báez, Sergio Enrique Meza-Toledo, Paola Muñoz-López, Luis Fernando Flores-Martínez, Karla Fraga-Pérez, Kevin Jorge, Magaño-Bocanegra, Uriel Juárez-Hernández, Armando Alfredo Mateos-Chávez et al.
Cancers 2022, 14(17), 4224; https://doi.org/10.3390/cancers14174224
Available online: https://www.mdpi.com/2072-6694/14/17/4224

2. “Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer”
by Ioannis A. Vathiotis, Tyler MacNeil, Jon Zugazagoitia, Konstantinos N. Syrigos, Thazin Nwe Aung, Aaron M. Gruver, Peter Vaillancourt, Ina Hughes, Steve Hinton, Kyla Driscoll et al.
Cancers 2021, 13(5), 1024; https://doi.org/10.3390/cancers13051024
Available online: https://www.mdpi.com/2072-6694/13/5/1024

3. “Hydrogen-Peroxide Synthesis and LDL-Uptake Controls Immunosuppressive Properties in Monocyte-Derived Dendritic Cells”
by Ann-Katrin Menzner, Tanja Rottmar, Simon Voelkl, Jacobus J. Bosch, Dimitrios Mougiakakos, Andreas Mackensen and Yazid J. Resheq
Cancers 2021, 13(3), 461; https://doi.org/10.3390/cancers13030461
Available online: https://www.mdpi.com/2072-6694/13/3/461

4. “Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires”
by Corinna Grunert, Gerald Willimsky, Caroline Anna Peuker, Simone Rhein, Leo Hansmann, Thomas Blankenstein, Eric Blanc, Dieter Beule, Ulrich Keller, Antonio Pezzutto et al.
Cancers 2022, 14(7), 1842; https://doi.org/10.3390/cancers14071842
Available online: https://www.mdpi.com/2072-6694/14/7/1842

5. “Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM”
by Georg Jeryczynski, Arnold Bolomsky, Hermine Agis and Maria-Theresa Krauth
Cancers 2021, 13(23), 5886; https://doi.org/10.3390/cancers13235886
Available online: https://www.mdpi.com/2072-6694/13/23/5886

6. “Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma”
by Samantha Pozzi, Alessia Bari, Martin Pecherstorfer and Sonia Vallet
Cancers 2021, 13(19), 4978; https://doi.org/10.3390/cancers13194978
Available online: https://www.mdpi.com/2072-6694/13/19/4978

7. “Intracranial Treatment in Melanoma Patients with Brain Metastasis Is Associated with Improved Survival in the Era of Immunotherapy and Anti-BRAF Therapy”
by Céline Dalmasso, Cécile Pagès, Léonor Chaltiel, Vincent Sibaud, Elisabeth Moyal, Ciprian Chira, Jean Christophe Sol, Igor Latorzeff, Nicolas Meyer and Anouchka Modesto
Cancers 2021, 13(17), 4493; https://doi.org/10.3390/cancers13174493
Available online: https://www.mdpi.com/2072-6694/13/17/4493

8. “Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas”
by Adrian Minson, Constantine Tam, Michael Dickinson and John F. Seymour
Cancers 2022, 14(5), 1276; https://doi.org/10.3390/cancers14051276
Available online: https://www.mdpi.com/2072-6694/14/5/1276

9. “Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8⁺ T Cells in Immunotherapy-Resistant and Metastatic Cancers”
by Jenny Dunn, Robert D. McCuaig, Abel H. Y. Tan, Wen Juan Tu, Fan Wu, Kylie M. Wagstaff, Anjum Zafar, Sayed Ali, Himanshu Diwakar, Jane E. Dahlstrom et al.
Cancers 2022, 14(6), 1596; https://doi.org/10.3390/cancers14061596
Available online: https://www.mdpi.com/2072-6694/14/6/1596

10. “Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article”
by Arthur Bobin, Cécile Gruchet, Stéphanie Guidez, Hélène Gardeney, Laly Nsiala Makunza, Mathilde Vonfeld, Anthony Lévy, Laura Cailly, Florence Sabirou, Thomas Systchenko et al.
Cancers 2021, 13(20), 5210; https://doi.org/10.3390/cancers13205210
Available online: https://www.mdpi.com/2072-6694/13/20/5210

11. “Diet as a Potential Moderator for Genome Stability and Immune Response in Pediatric Leukemia”
by Shanshan Wang, Christopher A. Maxwell and Neha M. Akella
Cancers 2021, 13(3), 413; https://doi.org/10.3390/cancers13030413
Available online: https://www.mdpi.com/2072-6694/13/3/413

12. “Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer Immunotherapy”
by Erwan Eriau, Juliette Paillet, Guido Kroemer and Jonathan G. Pol
Cancers 2021, 13(6), 1260; https://doi.org/10.3390/cancers13061260
Available online: https://www.mdpi.com/2072-6694/13/6/1260

13. “Efficacy and Safety of Immunotherapy for Cervical Cancer—A Systematic Review of Clinical Trials”
by Mona W. Schmidt, Marco J. Battista, Marcus Schmidt, Monique Garcia, Timo Siepmann, Annette Hasenburg and Katharina Anic
Cancers 2022, 14(2), 441; https://doi.org/10.3390/cancers14020441
Available online: https://www.mdpi.com/2072-6694/14/2/441

14. “The Potential of T Cell Factor 1 in Sustaining CD8⁺ T Lymphocyte-Directed Anti-Tumor Immunity”
by Sungmin Jung and Jea-Hyun Baek
Cancers 2021, 13(3), 515; https://doi.org/10.3390/cancers13030515
Available online: https://www.mdpi.com/2072-6694/13/3/515

15. “Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma—A Review”
by Arman S. Walia, Randy F. Sweis, Piyush K. Agarwal, Andrew K. Kader and Parth K. Modi
Cancers 2022, 14(1), 73; https://doi.org/10.3390/cancers14010073
Available online: https://www.mdpi.com/2072-6694/14/1/73

You can check more information about the Section “Cancer Immunology and Immunotherapy” in Cancers at the following link: https://www.mdpi.com/journal/cancers/sections/Cancer_Immunology_Immunotherapy.